COPE
Volume 1, Number 1 (Mar 2013)                   Res Mol Med (RMM) 2013, 1(1): 1-9 | Back to browse issues page




DOI: 10.18869/acadpub.rmm.1.1.1

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Valadan R, Rafiei A, Tehrani M, Nejatollahi F. Resistance to HER2-targeted therapy. Res Mol Med (RMM). 2013; 1 (1) :1-9
URL: http://rmm.mazums.ac.ir/article-1-35-en.html

Abstract:   (3417 Views)


Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug acquire resistance to it and experience tumor recurrence within 1 year. Several molecular and cellular mechanisms underlying the resistance to trastuzumab have been proposed. In this review, first, we provide a brief history leading to production of trastuzumab. Also we consider the cellular and molecular antitumor effects of trastuzumab and then, we discuss the mechanisms underlying trastuzumab resistance in four levels.

Full-Text [PDF 420 kb]   (1258 Downloads)    
Type of Study: Research | Subject: Immunology
Received: 2013/03/9 | Accepted: 2013/08/11 | Published: 2013/08/11

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author


© 2015 All Rights Reserved | Research in Molecular Medicine

Designed & Developed by : Yektaweb